Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Research & Development (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Research & Development for 5 consecutive years, with $10.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 40.21% year-over-year to $10.7 million, compared with a TTM value of $34.4 million through Dec 2025, up 13.56%, and an annual FY2025 reading of $34.4 million, up 13.56% over the prior year.
  • Research & Development was $10.7 million for Q4 2025 at SAB Biotherapeutics, up from $9.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $18.7 million in Q2 2021 and bottomed at $3.7 million in Q2 2023.
  • Average Research & Development over 5 years is $8.7 million, with a median of $7.7 million recorded in 2024.
  • The sharpest move saw Research & Development plummeted 65.96% in 2023, then skyrocketed 89.86% in 2024.
  • Year by year, Research & Development stood at $10.6 million in 2021, then plummeted by 32.6% to $7.2 million in 2022, then tumbled by 40.12% to $4.3 million in 2023, then soared by 78.05% to $7.7 million in 2024, then skyrocketed by 40.21% to $10.7 million in 2025.
  • Business Quant data shows Research & Development for SABS at $10.7 million in Q4 2025, $9.0 million in Q3 2025, and $7.0 million in Q2 2025.